Option Chain

BioNTech SE ADR

BNTXNASDAQ · USD

87.51USD+1.65 (+1.93%)

545

BioNTech SE ADR (BNTX) Option Chain

BioNTech SE ADR trades at $87.51, up 1.93%, with an IV Rank of 80.56%. This is high versus the past year, and the company carries a market cap of $21,568M in the Biotechnology industry. On the Nov 20, 2026 chain, the at the money $87.50 strike shows calls at $2.00 / $3.30 and puts at $2.75 / $5.70, both carrying about $3.43 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $92.50 calls, at 1,134 contracts, and the $95.00 puts, at 200, as of Nov 5, 2026.

Tracking the BNTX option chain helps you see every strike and expiry on BioNTech SE ADR in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of BNTX options activity at a glance. Use our scanner to monitor the BNTX option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For BNTX stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where BNTX options are being actively traded, and where they are not.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.

CALLs									PUTs
Prob. OTM %	Open Interest	Volume	Extrinsic Value	Intrinsic Value	Bid	Ask	Strike	Moneyness %	Bid	Ask	Intrinsic Value	Extrinsic Value	Volume	Open Interest	Prob. OTM %
36.12	0	0	0.64	5.01	4.20	7.10	82.50	-3.91	0.10	3.10	0.00	1.60	0	399	63.88
47.48	43	0	1.69	2.51	2.80	5.60	85.00	-1.00	2.05	3.00	0.00	2.53	16	463	52.52
58.72	38	571	2.64	0.01	2.00	3.30	87.50	+1.91	2.75	5.70	0.00	4.23	1	60	41.28
69.00	130	1	2.23	0.00	1.25	3.20	90.00	+4.82	4.40	7.50	2.49	3.46	0	222	31.00
77.75	2,057	1,134	1.20	0.00	0.65	1.75	92.50	+7.73	6.90	9.30	4.99	3.11	3	385	22.25

As of Nov 5, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

IndustryBiotechnology
SectorHealthcare
IV Rank80.56% High
Market cap (M$)21,568
52 weeks high-30.76%
52 weeks low7.97%
Analyst recommendationBuy
1.79
Target price$115.38
33.86% above the current stock price
Dividend—
Payout ratio—
Earnings date2026-11-03
P/E—
Future P/E—
EPS (ttm)-6.87
EPS growth next 5 years3.38%

As of Nov 5, 2026

Browse all Option Chain tickers